Why is ONCOblot® considered a game-changer in cancer prevention?

Medicor doctors have reviewed ONCOblot® research in detail, and have used the test for several months already. It is our opinion that ONCOblot® will radically change the face of secondary cancer prevention and treatment. The test allows ultra-early cancer detection, and is accessible to patients all over Canada. Since it is widely accepted by cancer specialists that the earlier a cancer is found, the easier it is to treat or cure, we feel the benefits of using this test will be profound. Currently we are not aware of any other test that can detect a cancer as early as ONCOblot®, and with the same level of accuracy. It can also identify the type of cancer, and is a simple, non-invasive test that involves no radiation exposure to the patient (unlike mammograms or CT scans). Only 1 test is needed to check the whole body for the presence of cancer.

For detection of some cancers and pre-cancers, there are excellent screening tests in use today (for example, Pap smears and colonoscopies). ONCOblot® is not meant to replace them, because they can detect abnormal cells before they become cancerous.  These abnormal cells can easily be removed. This process of preventing the cancer from actually developing is called primary prevention. ONCOblot® may be used to complement such tests.

However for many cancers there are currently no useful screening tests. We believe ONCOblot® has an immediate off-label role in ultra-early detection of these cancers (for example: ovarian, lung, pancreas, kidney and uterine). This is called secondary prevention. Also, cancers like breast and prostate have screening tools that are not very precise (such as PSA for prostate cancer and mammograms for breast cancer). We believe ONCOblot® has an immediate role in complementing standard screening tests for these cancers.

Certain approved screening tests like mammograms have some risks (such as repeated radiation exposure, and compression of the breast which can shed cancer cells if a tumour is present). In patient who avoid standard tests due to the risks, we believe ONCOblot® has an immediate role as a screening test.

To get tested at the Medicor office, please contact us. To find a nearby health professional where you can be tested, please see our Medicor Partners page.

What cancer types does ONCOblot® detect?
ONCOblot® detects and identifies the following cancer types: bladder, breast, colorectal, esophageal, gastric, hepatocellular, kidney, leukemia, lung (non-small cell), lung (small cell), lymphoma, melanoma, mesothelioma, myeloma, ovarian, pancreatic, prostate, sarcoma, squamous cell carcinoma, thyroid (follicular), thyroid (papillary), uterine (cervical), uterine (endometrial), uterine (other) and testicular germ cell. ONCOblot® also detects the presence of other cancers not on this list, but at this time, may not be able to identify the tissue of origin.
Will ONCOblot® detect 2 or more simultaneous cancers?
Yes. If there is more than one tissue of origin, then more than one type of ENOX2 protein would be revealed and the results would indicate each tissue of origin. Certain tests may show 2 cancer types, but they are actually just 1 cancer (for example, bile duct cancer may show a combination of hepatocellular and pancreatic).
What if I have a cancer that is not on the ONCOblot® list?
In that case, ONCOblot® will still identify the presence of cancer, and the tissue type will be unknown. For example, brain cancers are not currently on the list of 25 cancers. Brain cancers are still detected by the test, and are reported as “not in database”.
Will ONCOblot® identify if the cancer has spread (metastasized)?
ONCOblot® identifies the presence or absence of cancer (by identifying ENOX2 proteins), and the tissue type. It does not specify if the cancer is localized or has spread. For example, if the patient originally had colon cancer (which was surgically removed) and now the cancer recurs in the lungs and liver, ONCOblot® will indicate the presence of colon cancer.
Does ONCOblot® identify cancer stage, tumour grade or tumour burden?

These features of cancer are not measured by ONCOblot®.

Will ONCOblot® detect pre-cancerous cells, giving a false positive result?
ONCOblot® detects variations of the ENOX2 protein, which are produced by malignant cells and shed into the blood serum. ENOX2 proteins are only produced by malignant cells – cells that display uncontrolled growth and have the potential to invade other tissues or spread to other parts of the body. Normal cells and pre-cancerous cells do not produce ENOX2 proteins. Therefore, benign conditions will not produce false positives.
Will ONCOblot® detect breast DCIS (ductal carcinoma in situ) ?
Preliminary data indicates ONCOblot® can detect DCIS with high accuracy.
How often should I have the ONCOblot® test?
This depends on why you are doing the ONCOblot® test. If you are doing it to look for very early signs of recurrence after cancer treatment, we may recommend it annually or semi-annually. The more aggressive the cancer, the shorter the recommended time between tests (in order to pick up recurrence as early as possible). If you are healthy, but have a high cancer risk, we may recommend the test once every 1 to 3 years, depending on age and level of risk. When you have a consultation regarding the test, the optimal timing of the test for your unique situation will be discussed.
What does the current research say about the accuracy of ONCOblot® ?

MorNuCo Inc. has conducted research in several groups of patients, and also on preserved serum samples of research subjects with and without known cancers, to validate the accuracy of ONCOblot®. Medicor doctors have reviewed ONCOblot® research in detail, and our Medical Director has visited the lab facilities of MorNuCo in Indiana. The lab is CLIA-certified and CAP accredited. We have also conducted “blinded” testing, where we submitted samples of Toronto patients with known diagnoses to the lab (no information was given to the lab except patient age and sex) and results were in  agreement with confirmed medical information. This gives us confidence in the accuracy of the latest ONCOblot® data which shows the following:


  1. In a study of 110 healthy people with no known cancer, between the ages of 40 and 84 years, ONCOblot® detected the presence of cancer in 44 people (40%). A powerful natural therapy was administered. A total of 32 people completed the therapy (average of 8 months of treatment) and 30 (94%) showed a negative ONCOblot® cancer test after therapy. Out of the 12 who tested positive for cancer, 10 took treatment but then did not return for follow-up ONCOblot® testing. The other 2 did not take treatment and both were diagnosed with clinically apparent cancer, one within 10 months, and the other within 3 years.
  2. Detection Limit: ONCOblot® can detect the presence of 200 femtomoles of ENOX2 protein in 20 microlitres of blood serum, which corresponds to about 2 million cancer cells in the body. This is equivalent to the number of cells contained in a tumour about 1-2mm in diameter.
  3. Sensitivity: ONCOblot® has been shown to be 99.8% accurate in detecting / confirming cancer (by research conducted in over 1000 people with a known cancer). Further research was also conducted showing that ONCOblot® also has over 90% sensitivity when identifying stage 0 or stage 1 cancers.
  4. Specificity: ONCOblot® has been shown to be 99.93% accurate by not declaring a patient has cancer when they actually don’t. In other words, in 0.07% of cases, the test may falsely identify cancer when no cancer is actually present. This is equivalent to 1 false positive in 1500 patient cases.
  5. Correct tissue of origin: ONCOblot® correctly identifies the organ where the cancer came from in 96.7% of cases. In other words, in 1 out of every 30 cases, the test may identify the wrong tissue of origin. This happens mainly with early stage cancers. This accuracy was calculated from 1500 patient samples.

To read the current research papers, please see the ONCOblot® research page.

How exactly does ONCOblot® work?

ONCOblot® uses techniques known as two-dimensional gel electrophoresis and western blot analysis along with an ENOX2 protein-specific antibody. The result of the blood test is presented visually after processing. Each type of ENOX2 protein has a specific location (molecular weight and isoelectric point) on the blot to demonstrate ENOX2 presence and to identify the tissue of origin. In the example below, the circled spot indicates a lung cancer-specific ENOX2 protein. The two spots labeled R are references used for calibration. blot Based on a database containing a list of ENOX2 proteins and their corresponding cancer types, ONCOblot® is currently able to identify 25+ different cancer types from a single blood test. Rarely, one person can have more than one cancer –  ONCOblot® can identify more than one cancer type with a single test.

What are the steps involved in doing the ONCOblot® test?

1. Read and understand the ONCOblot® information on this website.
2. Locate a naturopathic doctor, medical doctor or other health professional who is a Medicor Partner and make an appointment for testing, OR if you are near the Medicor office in Toronto, you can make an appointment there. If you do not find a Medicor Partner close to home, you may ask a naturopathic doctor or other health professional close to home to become a partner with Medicor, then you may have the test done through them.
3. Have a blood sample taken for testing.
4. In about 3 weeks you should expect to receive a report.
5. If the report indicates there is no cancer present, book an appointment  to plan your cancer prevention strategy and discuss a follow-up testing schedule. If the report indicates the presence of cancer, book an appointment to formulate a suitable plan for further investigations and/or treatment (according to your doctor’s recommendations).

Is any special preparation needed for the ONCOblot® test?

No special preparation is needed for the  ONCOblot® test. There is no need to fast or stop any of your current medications.

How is blood drawn for the ONCOblot® test?

Blood draw for ONCOblot® is just like most routine blood tests. The size of needle does not affect the test (butterfly needles may be used). One SST tube of blood (included in the ONCOblot® kit) should be adequate for the test. In a situation where there is difficulty drawing a full tube of blood, the lab needs a final serum volume of 0.1ml. The blood must be centrifuged to separate the serum, which is then transferred to another tube and frozen. The frozen serum is labelled and shipped overnight with an ice pack (included in the kit) to the ONCOblot® lab Monday, Tuesday or Wednesday only. The frozen serum can be stored indefinitely prior to shipping.

How long does it take to get the ONCOblot® test result?

Lab processing time is about 14 business days, but you should expect your results in about 3 weeks. Blood samples must be frozen overnight, and frozen samples are only shipped Monday to Wednesday to prevent any potential shipping delay from spoiling the sample (if the shipment is delayed and held up over the weekend). As a result, if you had your blood taken on Wednesday, Thursday or Friday, there will be a few days extra delay.

If you have not received your report by 4 weeks, please contact the health professional who has ordered your test.

My cancer treatment is complete and I am in remission. When should I do the ONCOblot® test?

Once your treatment is complete and there is no evidence of cancer by standard testing methods, we suggest waiting about two months before having an ONCOblot® test. This small delay is recommended because it takes time for circulating ENOX2 proteins to be cleared from the body. The timing for each patient should be based on their medical history and the physician’s clinical judgment.

If ONCOblot® is performed 2 months after completion of cancer therapy, and the test result is positive, it means a small amount of cancer remains in the body. This indicates that ongoing non-toxic maintenance therapy is needed, not a “watch and wait” approach.

How does ONCOblot® compare to DNA and other advanced cancer detection tests?

ONCOblot® looks for proteins called ENOX2 that are only present in cancer cells, not in healthy cells. That makes the test very accurate. Some tests are currently available that identify tiny amounts of cancer DNA fragments in the blood. These tests are also highly sensitive like ONCOblot®, but not as accurate since they rely on matching the DNA fragments to a database containing cancer DNA sequences. We don’t know all the DNA sequences that cancers contain, and cancers often mutate, causing changes in DNA. In our opinion, this is a significant limitation of these types of tests, for cancer detection and confirmation. Furthermore, there is not enough research yet for us to recommend circulating DNA cancer blood tests.

What does it mean if I have a positive ONCOblot® test result?

If you have had the ONCOblot® test done and it shows the presence of a cancer, it means that there is over a 99% chance that you do in fact have cancer*. Since the test does not tell how advanced the cancer is, it might mean the cancer is very small. Perhaps so small that your body will naturally control or fight off the cancer with no treatment. Tiny cancers also can often be treated or cured with gentle therapies or minimally-invasive surgery.

If the cancer is very small (1-2 mm for example), standard imaging test like ultrasound, x-ray, MRI, CT scan or PET scan may not detect it. Standard cancer blood tests (like PSA or CEA) also may be completely normal. If your doctor is not familiar with the high sensitivity of ONCOblot®, they may orders standard cancer blood tests or a scan and find no evidence of cancer. Then they could advise you there is no cancer. You should be aware of this possibility before getting the ONCOblot® test done. In these types of cases, we ask the patent to have their physician contact us for more information about ONCOblot® so we can explain the correct interpretation and action plan. Waiting while taking no action is not an appropriate plan, and defeats the purpose of doing the ONCOblot® test in the first place.

If the cancer is larger and is detected on a scan, it may require more aggressive treatment. This may involve confirming the diagnosis by biopsy and standard therapy through your local cancer hospital. In some cases, gentler therapies like off-label medicines (prescribed through your naturopathic doctor or Medicor doctor) can be used. Once ONCOblot® determines there is cancer, a biopsy is not always required. However, biopsy is considered standard medical practice when cancer is suspected, and normally is required prior to standard cancer therapies (like chemo or radiation).

* based on the latest available research data from MorNuCo Inc.

What does it mean if I have a negative ONCOblot® test result?

If you have had the ONCOblot® test done and it does not detect any cancer, it means there is over a 90% chance that you don’t have cancer. All tests have limits of detection. ONCOblot® can detect as little as 2 million cancer cells in the body (equivalent to a 1-2 mm tumour). ONCOblot® can even detect the cancer cells if they are not collected together into a tumour. If there are less than 2 million cancer cells in the body, ONCOblot® will not detect it.

If your ONCOblot® test is negative, there is a small chance that you have a tiny number of cancer cells that are not yet detectable. Also a negative test doesn’t mean that your risk factors for getting cancer go away. Cancer prevention strategies should still be used. Repeat ONCOblot® testing should be arranged by your doctor on a schedule that is appropriate for your individual situation.

I would like to know more about the doctors who developed ONCOblot®
D. James Morré, Ph.D. and Dorothy M. Morré, Ph.D. are the developers of the ONCOblot® Test, a Laboratory Developed Test for early cancer detection. The Morré’s are committed to the premise that understanding cancer is the key to its conquest. Their ONCOblot® test, a new blood test for cancer, is based on more than 20 years of basic research.

D. James Morré, Ph.D.

  • President, CEO and Director of Research, MorNuCo, Inc, Purdue Research Park, West Lafayette, IN.
  • Formerly Dow Distinguished Professor of Medicinal Chemistry, School of Pharmacy, Purdue University.
  • Ph.D. Biochemistry, California Institute of Technology, Pasadena, CA (1963)
  • Founding Director of the Purdue Cancer Center (1976-1986)
  • Purdue University Society of Sigma Xi Faculty Research Award (2004)
  • More than 750 papers and reviews published, listed among the 300 most-cited authors in science by Current Contents with 3065 citations for the 14 year period between 1965-1978.
  • Placed above the 95th percentile in the distribution of extramural NIH funds over the past 24 years based on the Columbia University study of NIH records (2006).

   Dorothy M. Morré, Ph.D.

  • Vice President, CSO and Treasurer, MorNuCo, Inc, Purdue Research Park, West Lafayette, IN.
  • Ph.D., Nutrition, Purdue University 1977
  • Research Scientist, Division of Membrane Biology and Biochemistry, Institute of Experimental Pathology, German Cancer Research Center, Heidelberg, Germany (1976).
  • Formerly, Professor, Department of Foods and Nutrition, Purdue University.
  • Gamma Sigma Delta Award for Outstanding Performance and Achievement in Research, Purdue University (2004)
  • Founding Member, Botanical Center-Age Related Disease, Purdue University. 170 publications
  • Co-discoverer of ENOX family of cell surface proteins and co-author of book with D. James Morré “ECTO-NOX Proteins” published by Springer, New York (2013).
Is ONCOblot® approved by FDA or Health Canada?

MorNuCo Inc. is in the process of seeking FDA approval – a 510(k) is being prepared for submission to the FDA, along with plans to seek insurance coverage. The test currently meets FDA guidelines for a Laboratory Developed Test (LDT). The ONCOblot® lab is CLIA Certified (Clinical Laboratory Improvement Amendments). The CLIA license is 15D2033610. CLIA is a quality assurance certification. ONCOblot® is also CAP Accredited (College of American Pathologists). This confirm compliance with scientifically endorsed laboratory standards, and accuracy of test results to ensure accurate patient diagnosis. Health Canada approval for ONCOblot® is in the preliminary stage of exploration.

I am not in Canada, how can I get the ONCOblot® test?

Please have a look at the ONCOblot® labs website. The test is currently available in China, Hong Kong, Poland, Russia, Switzerland, Taiwan, Ukraine, United Kingdom, and of course USA.

What is the cost of the ONCOblot® test?

The price of the test at Medicor is currently $1700 (Canadian). This includes taking the blood sample from a vein or PICC line, processing the blood before shipment (centrifugation / serum separation / serum freezing) and refrigerated express shipping of the blood serum to the lab in USA. There is a small additional fee for blood draw from a Port-A-Cath® or other similar implanted catheter. If you are getting the test done from your own health professional, the price may be slightly different. Since the test is performed in USA, the price will be adjusted if there is a significant change in the Canadian/US dollar exchange rate.

I noticed the ONCOblot® test price is different in USA, can I get the same price in Canada?

The price of the ONCOblot® test is advertised as $850US at many clinics in USA. This is the price of the test alone, and does not include fees for doctor’s visits for counseling or blood collection and processing, In Canada, Medicor has chosen to bundle all the costs, so there are no last-minute extra charges. Other costs that are taken into account when setting the Canadian price are: US / Canadian exchange rate, bank fees for currency exchange, credit card fees, additional cost of express overnight shipping from Canada to USA, legal fees, medical consulting, IT support, web development and administrative support to make the test available to medical and naturopathic doctors across Canada and to educate them on its use.

If there is a significant change in Canadian / US exchange rate, the Canadian price will be adjusted accordingly, and all Canadian ONCOblot® partners will be updated with the new rate.